BenevolentAI Past Earnings Performance
Past criteria checks 0/6
BenevolentAI has been growing earnings at an average annual rate of 4.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 55.8% per year.
Key information
4.2%
Earnings growth rate
121.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -55.8% |
| Return on equity | -73.1% |
| Net Margin | -1,056.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is BenevolentAI (AMS:BAI) In A Good Position To Invest In Growth?
Sep 24
Is BenevolentAI (AMS:BAI) In A Good Position To Invest In Growth?
Jun 07We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate
Dec 23BenevolentAI S.A. (AMS:BAI) Analysts Just Trimmed Their Revenue Forecasts By 24%
Jun 22BenevolentAI S.A. (AMS:BAI) Analysts Just Cut Their EPS Forecasts Substantially
Apr 26BenevolentAI S.A. (AMS:BAI) Analysts Just Slashed This Year's Revenue Estimates By 20%
Apr 08Will BenevolentAI société anonyme (AMS:BAI) Spend Its Cash Wisely?
Dec 10We're Keeping An Eye On BenevolentAI société anonyme's (AMS:BAI) Cash Burn Rate
Jul 23Revenue & Expenses Breakdown
How BenevolentAI makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -51 | 22 | 44 |
| 31 Mar 24 | 6 | -57 | 23 | 51 |
| 31 Dec 23 | 7 | -63 | 23 | 57 |
| 30 Sep 23 | 9 | -61 | 19 | 63 |
| 30 Jun 23 | 11 | -59 | 14 | 69 |
| 31 Mar 23 | 11 | -112 | 69 | 71 |
| 31 Dec 22 | 11 | -164 | 125 | 72 |
| 30 Sep 22 | 9 | -186 | 141 | 69 |
| 30 Jun 22 | 8 | -208 | 157 | 66 |
| 31 Mar 22 | 6 | -158 | 106 | 61 |
| 31 Dec 21 | 5 | -108 | 56 | 57 |
| 31 Dec 20 | 7 | -55 | 52 | 20 |
| 31 Dec 19 | 5 | -48 | 41 | 21 |
| 31 Dec 18 | 7 | -27 | 40 | 0 |
Quality Earnings: BAI is currently unprofitable.
Growing Profit Margin: BAI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAI is unprofitable, but has reduced losses over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare BAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).
Return on Equity
High ROE: BAI has a negative Return on Equity (-73.07%), as it is currently unprofitable.